分类： health

Thirty-six-year-old Michael Nalewaja had built a stable, quiet life as an electrician in Alaska, nearly 20 years removed from a teenage battle with drug addiction that led him to rehabilitation. That peaceful existence ended abruptly just days before Thanksgiving 2025, when Nalewaja and a mutual friend unknowingly consumed a deadly combination of fentanyl and carfentanil, which they had mistaken for cocaine.

Kelley Nalewaja, Michael’s mother, recalled the devastating phone call she received from her son’s wife: “I heard the word ‘autopsy’ and I literally just collapsed to the floor. Even if somebody had been there prepared with Narcan — even if somebody had called 911 in time — he was not going to survive.”

Michael’s death is far from an isolated tragedy. Authorities are now sounding the alarm over a dramatic resurgence of carfentanil, a weapons-grade synthetic opioid 10,000 times more potent than morphine and 100 times stronger than standard fentanyl, that has killed hundreds of unsuspecting drug users across the United States. This growing public health threat has emerged against a backdrop of an unprecedented multi-year decline in both overall drug overdose deaths and fentanyl seizures, a shift that experts and law enforcement trace to new regulatory controls.

Following a recent Chinese government crackdown on the sale of chemical precursors used to manufacture illicit fentanyl, Mexican drug trafficking organizations have turned to carfentanil to boost the potency of diluted fentanyl supplies, according to Drug Enforcement Administration (DEA) intelligence bulletins reviewed by The Associated Press. This is not the first time carfentanil has penetrated the North American drug market: a decade ago, the substance caused a wave of mass overdoses before Chinese regulatory controls and U.S. enforcement cracked down on its supply, driving incident numbers sharply down.

That trend has reversed dramatically in just a few short years. DEA laboratory data obtained by the AP shows that agents identified carfentanil in 1,400 separate drug seizures across the U.S. in 2025. That number marks a drastic jump from just 145 positive identifications in 2023 and only 54 in 2022. Law enforcement officials say Mexican cartels are now either experimenting with domestic carfentanil production or sourcing the substance from Chinese vendors who evade Beijing’s regulations by advertising on unregulated online forums hosted in third countries.

Manufacturing carfentanil carries extreme risk even for experienced traffickers, notes Frank Tarentino, the DEA’s chief of operations for the Northeast region covering Maine to Virginia. “You can’t just dabble in this. This is not some mad scientist on Reddit you’re going to get to go out to a rudimentary laboratory in Mexico to make carfentanil,” he explained. For people struggling with opioid dependence who purchase unregulated drugs on the street, the risk is unparalleled: a dose smaller than a grain of salt is enough to cause lethal overdose, and even high multiple doses of naloxone — the life-saving overdose-reversing medication — are often ineffective against carfentanil exposure. “This presents an extremely frightening proposition for substance abuse dependent people who seek opioids on the street today,” Tarentino added.

The resurgence of carfentanil comes at a moment of rare progress in the U.S. overdose crisis. Overall drug overdose deaths have fallen for more than two years, the longest sustained decline in decades. Experts attribute this drop to multiple factors, including wider distribution of naloxone, expanded access to evidence-based addiction treatment, and international regulatory changes targeting fentanyl precursor production. Fentanyl seizures at the U.S. border have also plummeted: U.S. Customs and Border Protection reports that seizures fell to roughly 12,000 pounds in 2025, less than half the total seized in 2023.

Even with this progress, the DEA has maintained fentanyl and emerging synthetic opioids as its top enforcement priority, recently requesting a $362 million budget increase focused exclusively on combating cartel-driven trafficking. Sara Carter, the White House drug czar under the current administration, framed the crisis as an deliberate act of harm. “Anyone who takes a pill that is not prescribed to them by their doctor is playing a game of Russian roulette with their life,” Carter said. “But if those terrorists think they can continue this chemical warfare without consequences, they are wrong.”

Public health experts and drug policy specialists warn that carfentanil’s unique deadliness makes its resurgence an especially alarming threat. Originally developed and researched for use as a chemical weapon, carfentanil was infamously deployed by Russian forces against Chechen separatists during a 2002 hostage crisis. Today, the only legal use for the substance in the U.S. is as a tranquilizer for large zoo animals such as elephants, with the DEA capping annual legal manufacturing at just 20 grams — an amount small enough to fit in the palm of a hand.

“If the world thinks we had a problem with fentanyl, that’s minute compared to what we’re going to be dealing with with carfentanil,” said Michael King Jr., founder of the Opioid Awareness Foundation, comparing the substance to a biological weapon. The most recent Centers for Disease Control and Prevention data underscores this risk: in 2024, overdose deaths linked to carfentanil nearly tripled from the previous year, totaling 413 deaths across 42 states and Washington, D.C. While carfentanil’s overall prevalence still trails that of standard fentanyl, experts warn it could spread rapidly across the country without targeted law enforcement intervention to cut off supply chains.

In recent months, the DEA has already intercepted large shipments of carfentanil-laced counterfeit pills. In October 2025, the agency’s Los Angeles field division seized 628,000 pills laced with carfentanil; just one month prior, officials in Washington state seized more than 50,000 counterfeit M30 opioid pills at a gas station, which tested positive for a lethal mixture of carfentanil and acetaminophen.

Traffickers are drawn to carfentanil for the same economic reason that drove the rise of fentanyl years ago: extremely small amounts can produce a massive supply of cut street drugs, generating enormous profits. Rob Tanguay, senior medical lead for addiction services at Canadian health agency Recovery Alberta, added that some frequent opioid users who have developed tolerance to standard fentanyl actively seek out carfentanil for its more intense high, despite the well-documented lethality. “The toughest part about all of this is that this is all about money,” Tanguay said.

For Kelley Nalewaja, the loss of her son — a charismatic electrician who recently earned a national award from his industry union — has turned private grief into public advocacy. Instead of holding a large funeral, she organized a community town hall in her hometown of El Dorado Hills, California, bringing together local leaders and other bereaved families who have lost loved ones to illicit synthetic opioids. She is now pushing for sweeping legislative and policy changes to curb carfentanil trafficking, arguing the substance was never intended for human consumption. “It’s not an OD; it’s not an overdose,” she said. “It’s a murder weapon.”

On a clear, cool morning in mid-April, residents and religious practitioners in Namling County of the Xizang Autonomous Region came together at their local community activity center, ready to take part in a routine health screening that has become a cornerstone of public care across the region’s high-altitude landscapes. Standing at over 4,100 meters above sea level, this remote gathering is just one of hundreds of stopovers for the mobile medical teams that traverse Xizang’s rugged terrain each year, delivering a full suite of preventive care services that include blood pressure monitoring, ultrasound diagnostics, and comprehensive chronic disease screenings that would otherwise be out of reach for many isolated communities.

This groundbreaking free health checkup initiative, first rolled out region-wide in 2013, has grown from a targeted pilot project to a near-universal public health infrastructure that prioritizes equity for all residents of Xizang, regardless of their geographic location. Funded through annual government per-capita subsidies, the program began with an allocation of 100 yuan (approximately 14 USD) per resident, and over more than a decade of operation, has facilitated a total of 22.41 million free checkups that cover nearly the entire population of the region.

By 2025, growing policy commitment and increased public investment have lifted the annual per-capita subsidy to 164 yuan, with additional earmarked funding to expand the fleet of mobile diagnostic vehicles and upgrade local clinic facilities in the most hard-to-reach mountainous and high-altitude areas. To address the greater health needs of aging residents, the subsidy for adults aged 65 and older is even higher, reaching 200 yuan per person annually to support more comprehensive, detailed screenings.

At its core, the program is designed to prioritize early detection and proactive management of common health conditions that disproportionately affect high-altitude populations, including hypertension, diabetes, and a range of altitude-related illnesses. Tailored screening and care pathways for vulnerable groups — including the elderly, women of reproductive age, and children — have already delivered measurable public health gains: regional data shows consistent reductions in maternal mortality, alongside marked improvements in long-term management of chronic conditions across communities.

The reach of the initiative extends beyond rural villages to include religious communities, with mobile teams regularly conducting checkups at local monasteries. For Phurbu, a monk at Dragkar Monastery, the program has transformed his approach to personal health. “Regular screenings allowed me to detect and manage hypertension early,” he explained, noting that consistent access to free preventive care has significantly improved his overall quality of life.

Health policy experts note that Xizang’s decade-long investment in this proactive, community-focused public health program underscores the regional government’s sustained commitment to delivering equitable, accessible healthcare to all residents, even in the world’s most challenging high-altitude environments. As subsidies and infrastructure continue to expand, the program is set to further reduce health disparities and improve long-term well-being for millions across the region.

For nearly 20 years, the global medical community has been locked in a contentious debate over whether adjunct hormone therapy can cut the risk of dangerous cardiovascular complications in children with Kawasaki disease, a poorly understood systemic vasculitis that disproportionately affects young kids. Now, a landmark five-year clinical study led by Shanghai’s Children’s Hospital of Fudan University, in partnership with 28 additional medical institutions across China, has delivered a clear, data-backed answer that is reshaping clinical guidelines worldwide.

Kawasaki disease, which triggers inflammation of blood vessels throughout the body, is diagnosed annually in 1 out of every 1,000 children under age 4 in China, and incidence rates are rising across East Asia, the region with the world’s highest prevalence of the condition. While a standard international treatment protocol exists, 10 to 20 percent of patients still develop coronary artery lesions — the disease’s most life-threatening complication — and 0.5 to 1 percent of treated children develop giant coronary artery aneurysms that compromise long-term health and survival. For decades, researchers have searched for additional therapies to improve outcomes, leading to conflicting investigations into the benefits of hormone therapy to reduce inflammation. Past studies were limited by small sample sizes, inconsistent hormone dosing protocols, and heterogeneous patient populations, leaving clinicians around the world with conflicting guidance and widespread uncertainty in daily practice.

Launched in 2021, this new multicenter randomized controlled trial — the largest study of its kind ever conducted globally — enrolled more than 3,200 participants, with 3,058 patients completing full follow-up for the study’s primary endpoint. Researchers compared rates of coronary artery complications between patients who received hormone therapy alongside standard treatment and those who received standard treatment alone, assessing outcomes at two weeks, one month, and three months after disease onset. The trial found no statistically significant difference in coronary artery lesion rates between the two groups. Even more critically, the research revealed that for patients who do not respond to initial standard treatment, adding hormone therapy actually increases the risk of developing coronary complications.

The study’s findings were published online Thursday in the *New England Journal of Medicine*, one of the world’s most prestigious general medical publications. Global medical experts have hailed the research as a transformative contribution to Kawasaki disease care, noting that it will immediately cut unnecessary hormone overuse in treatment, while providing a critical foundation for future research into targeted therapies.

Jane W. Newburger, a leading U.S. cardiologist specializing in pediatric cardiovascular disease, emphasized that future research must move beyond broad anti-inflammatory approaches like hormone therapy to identify the specific biological drivers of tissue-level inflammation, which will enable development of targeted treatments for children at highest risk of life-threatening complications.

Wang Yi, president of the Children’s Hospital of Fudan University, noted that the landmark findings will open new avenues of investigation into Kawasaki disease. The hospital treats more than 7,000 international pediatric patients annually, most with complex, life-threatening conditions, and Wang added that leading high-impact research like this trial will advance clinical practice globally, strengthen medical discipline development, and support Shanghai’s growing role as an international medical hub.

The study addresses a longstanding gap in global pediatric care, offering clarity that will immediately improve clinical decision-making and set the trajectory for the next generation of life-saving treatments for this high-stakes childhood disease.

On Monday, a landmark step forward in the management of allergic diseases emerged from China’s capital, as the Beijing University of Chinese Medicine unveiled the nation’s first fully integrated traditional Chinese medicine system that unites theoretical research, clinical application, translational research development, and professional talent cultivation.

Unlike fragmented approaches that have historically separated these core components of medical advancement, this new interconnected framework represents a growing institutional push to address a widespread public health burden that impacts hundreds of millions of people across China. The system’s foundational roots lie in the TCM constitution theory developed by Wang Qi, an academician of the Chinese Academy of Engineering.

Moving beyond the reactive, symptom-focused care that often targets immediate allergic reactions such as sneezing, skin itching, and rashes, the framework adopts a holistic, three-pronged diagnostic approach that evaluates a patient’s overall physical constitution, specific underlying allergic predisposition, and current presenting symptoms. Its core goal is to correct the deeper internal bodily imbalances that trigger allergic reactions at their source, rather than just managing flare-ups after they occur. This patient-centered model delivers customized long-term management plans tailored to each individual’s unique physiological profile.

At the heart of the new system is a three-tier prevention strategy aligned with core TCM principles. The first tier focuses on stopping allergic symptoms before they start by supporting overall bodily health, the second targets early intervention to stop conditions from worsening, and the third works to reduce the chance of recurrence after patients recover.

To turn this theoretical framework into accessible clinical care, the university has launched a cross-institutional allergy treatment alliance across all its affiliated hospitals, alongside the rollout of specialized multidisciplinary allergy clinics. Standardized evidence-based herbal formulas and evidence-backed external TCM therapies have also been introduced to ensure consistent, high-quality care across participating sites.

On the education and global outreach side, Yan Zhanfeng, vice-president of the university’s Dongzhimen Hospital, announced the launch of an international training program focused on integrative allergology. The initiative is designed to cultivate a new generation of medical professionals with expertise in both traditional Chinese medicine and modern immunology.

Liu Cunzhi, vice-president of the Beijing University of Chinese Medicine, noted that the program deepens cross-sector integration between academic research, frontline clinical care, and the healthcare industry. Beyond meeting domestic public health needs, the initiative aims to share Chinese medical expertise with the global community working to address the rising global burden of allergic diseases.

The Hong Kong Special Administrative Region (HKSAR) is set to roll out an expanded ban on e-cigarettes and other alternative smoking products, with restrictions on public possession and use set to take effect on April 30, building on sweeping trade-focused regulations introduced in 2022.

Under the new policy, the HKSAR Department of Health confirms that it will become a criminal offense for any individual, whether local resident or visitor, to possess or consume alternative smoking products — a category that includes e-cigarettes, heated tobacco products, and herbal cigarettes — across all public spaces once the rule enters into force.

Penalties for violations are structured to match the severity of the offense: casual offenders, including tourists who break the rule, face an immediate fixed fine of HK$3,000 (equivalent to roughly $383 USD). For individuals found carrying quantities of prohibited products that exceed legally set thresholds, which suggests potential intent for commercial distribution, consequences rise to a maximum fine of HK$50,000 and up to six months of imprisonment.

This latest measure strengthens the original 2022 ban, which already criminalized the import, promotion, manufacturing, sale, and commercial possession of these alternative smoking products, closing a regulatory gap that previously allowed personal possession in public spaces.

The policy expansion has drawn widespread discussion on social media platforms across the Chinese mainland, with the overwhelming majority of users expressing clear support for the new rule. Many mainland users noted the ban would not discourage them from traveling to Hong Kong, and went a step further to call for mainland Chinese cities to adopt similar strict regulations to reduce public exposure to secondhand smoke and harmful vapor.

Sonia Liu, a Shanghai resident who has traveled to Hong Kong multiple times, said she fully backs the HKSAR government’s tobacco control efforts, noting that stricter rules will improve the experience for non-smoking visitors and ultimately encourage more tourist visits to the city.

“Hopefully, these measures can be strictly enforced, especially by screening tourists who intend to dodge them and imposing appropriate penalties,” Liu said. She also recommended that authorities ramp up public outreach, including posting clear warning signs at border checkpoints and running more widespread awareness campaigns on advertisements and billboards, to prevent visitors from accidentally violating the regulation out of ignorance.

Eva, a Shenzhen resident who makes frequent cross-border trips to Hong Kong, also voiced support for the new rules but suggested that first-time offenders who unknowingly break the ban should be given more lenient treatment rather than facing full penalties immediately.

Local opinions in Hong Kong are largely supportive, though some residents have raised questions about the scope of penalties. A Hong Kong resident surnamed Liu acknowledged that stricter legislation will help create a cleaner, healthier public environment, but questioned whether penalizing individuals simply for carrying unused e-cigarettes is excessively harsh. Another local resident, Jack So, agreed that the ban will cut down non-smokers’ exposure to secondhand vapor and deliver widespread public health benefits, but expressed hope that the regulation will eventually be expanded to cover all tobacco products to create a fully smoke-free city.

Legislator Rebecca Chan Hoiyan framed the expanded ban as a key step to cement Hong Kong’s goal of becoming a smoke-free city, arguing that the initiative will actually boost the city’s appeal to international and domestic tourists by prioritizing public health. Addressing widespread concerns that the new restrictions could harm Hong Kong’s tourism sector, Chan pointed out that the city’s core attractions — its unique blend of Eastern and Western cultures, rich intangible cultural heritage, and diverse leisure offerings — far outweigh any concerns related to tobacco rules.

David Lam Tzit-yuen, the Legislative Council representative for the medical sector, noted that a full, comprehensive ban on alternative smoking products sends an unambiguous public health message that these harmful products are not tolerated in Hong Kong. He described the April 30 expansion as a landmark milestone in the city’s decades-long push to raise a smoke-free new generation free from the health risks of tobacco and alternative smoking products.

Hong Kong has built a multi-pronged, progressive tobacco control strategy dating back to the 1980s. Already, smoking is prohibited in a wide range of public spaces, including all public transport, indoor public venues, and outdoor public areas such as schools, public parks, and cinemas, with existing violations carrying the same fixed HK$3,000 penalty. In addition to strict spatial restrictions, the government also imposes high excise taxes on conventional tobacco products: a standard pack of major-brand cigarettes retails for approximately HK$105, with taxes making up roughly 63 percent of the final retail price to discourage consumption.